Thks Jakey but we specifically need data on daily dose of low dose aspirin in the JELIS population Kiwi
ps
From your link ( thx for that by the way )
In a meta-analysis of two studies examining use of low-dose aspirin therapy for secondary prevention, adherence was found to be approximately 65% (95% CI 53–77).
Amrn like aspirin. I say "like" In that aspirin as you quote is taken by so many individuals that it's not indicated for. Most of them are taking it bc a friend told them too or they read it may help or some they're doc said to. However Aspirin doesn't help for primary prevention of heart disease or stroke but the numbers are so good for secondary prevention people extrapolate that. Same with amrn if reduce it is a success. The market potential is massive if it can show a mortality benefit especially. Food for thought.
News 
Market Data 
Discover 
AI
